CBIH: Potential Rescheduling to Schedule III Could Reward Decades of Scientific Preparation and Regulatory Discipline
MWN-AI** Summary
Cannabis Bioscience International Holdings, Inc. (CBIH), trading under the ticker CBIH (OTCID: CBIH), provided a promising update as discussions intensify around a potential executive order from President Donald Trump aimed at rescheduling cannabis from Schedule I to Schedule III. CBIH, led by CEO Dante Picazo, views this change as a monumental shift for federal cannabis policy, potentially enhancing research access, pharmaceutical development, and medical adoption.
Positioned as a leader in the cannabis space, CBIH credits its preparedness over the years as a key strength. The company has concentrated on developing intellectual property, standardizable formulations, and scalable scientific platforms while prioritizing educational initiatives. This strategic focus differentiates CBIH as it seeks to advance cannabis as an evidence-based medicine. Dr. Rosangel Andrades, Research Director at CBIH, highlighted their readiness for an impending regulatory shift and emphasized a commitment to elevate scientific standards and operational excellence.
The company argues that a move to Schedule III could pave the way for a more robust investment landscape, attracting institutional investors by standardizing research conditions and creating clearer medical positioning. CBIH references economic projections indicating that legal cannabis sales in the U.S. may exceed $31.4 billion in 2024, with further growth expected to $53.5 billion by 2027. This data underscores the industry's potential as regulatory clarity improves.
Looking forward, CBIH plans to enhance its scientific model, foster strategic partnerships, and prioritize applied research in anticipation of regulatory changes. The company's objective is to translate regulatory clarity into tangible benefits for patients and healthcare professionals, ensuring that they remain at the forefront of the evolving cannabis industry landscape.
MWN-AI** Analysis
Cannabis Bioscience International Holdings, Inc. (CBIH) stands at a pivotal juncture with the potential federal rescheduling of cannabis from Schedule I to Schedule III. This shift could open the floodgates for increased research and development opportunities, fundamentally transforming how the cannabis industry operates. As CBIH's CEO, Dante Picazo, highlights, this energetic regulatory environment is a culmination of years of strategic preparation. The company has leveraged its commitment to rigorous scientific standards, laying the groundwork for what could become a leading position in evidence-based cannabinoid medicine.
From an investment perspective, this potential rescheduling, spearheaded by supportive government initiatives, signals a significant shift in market sentiment. CBIH is well-positioned to benefit from increased institutional interest as regulatory clarity helps legitimize cannabis as a healthcare product. This could make CBIH a compelling option for investors, especially with forecasts like Whitney Economics projecting legal cannabis sales in the U.S. to surpass $31.4 billion in 2024 and to reach $53.5 billion by 2027.
Furthermore, CBIH's disciplined approach, employing robust intellectual property protections and high standards in product formulations, allows it to distinguish itself from competitors who have not adopted such rigorous practices. The emphasis on education and industry standards not only enhances their credibility but may also attract investment through a more favorable risk-reward profile.
Investors should monitor CBIH's performance closely, especially as developments regarding federal rescheduling unfold. If successful, becoming a Schedule III substance could lead to increased market share, new partnerships, and ultimately, higher returns as the cannabis landscape evolves. In summary, CBIH's strategic foresight not only prepares it for potential regulatory shifts but also aligns with the broader economic trends favoring cannabis, making it a strong candidate for investors seeking exposure in this burgeoning industry.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Houston, Texas--(Newsfile Corp. - December 15, 2025) - Dante Picazo, CEO of Cannabis Bioscience International Holdings, Inc. trading under ticker symbol CBIH (OTCID: CBIH), provided the following update in light of recent reports suggesting that President Donald Trump may issue an executive order aimed at accelerating the federal process of rescheduling cannabis from Schedule I to Schedule III.
CBIH believes that, if the process moves forward, it could represent one of the most consequential federal shifts since the 1970s. CBIH views Schedule III as a bridge toward improved research access, clearer pharmaceutical development pathways, and more responsible medical adoption.
In that historical context, CBIH emphasizes that its advantage has not been speculation, but sustained preparation for an increasingly demanding regulatory environment. The Company has focused its strategy on pillars that often distinguish a "consumer" industry from a "healthcare" industry: intellectual property, standardizable formulations, scalable scientific platforms, and educational programs designed to elevate medical and regulatory standards. With this approach, CBIH states that it has positioned itself to actively contribute to the advancement of cannabis as evidence-based medicine.
"We have prepared for this moment with a long-term vision," said Rosangel Andrades, MD, Research Director at CBIH. "If rescheduling to Schedule III becomes a reality, our next step is to further strengthen our scientific standards and advance toward a 'Magnet-ready' level of institutional excellence in the science of cannabinoids as medicine, with processes, clinical evidence, and operational quality aligned with the highest best practices in the healthcare sector."
"CBIH believes that Schedule III can support a more investable environment that is more attractive to institutional capital by enabling more standardized research conditions, clearer medical positioning, and improved operating realities for companies that comply with applicable regulatory frameworks, quality standards, and responsible corporate governance practices," said John Jones, Board Director of CBIH.
From an economic standpoint, the scale is already undeniable: Whitney Economics projected that legal cannabis sales in the United States would exceed $31.4 billion in 2024, representing an increase of approximately $2.6 billion versus 2023 (about 9.14% year over year). In parallel, industry employment estimates place the legal market at 425,002 jobs supported across the United States. Looking ahead, sector analyses have projected that legal retail cannabis sales in the United States could exceed $53.5 billion by 2027, reflecting the magnitude of the potential growth if regulatory expansion continues.
Looking to 2026, CBIH expects to accelerate initiatives that strengthen its scientific and educational model, expand strategic partnerships, and advance developments focused on standardization, applied research, and responsible medical adoption, with the goal of converting regulatory clarity into measurable progress for patients, healthcare professionals, and funding institutions.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.x.com/CBIHIR/
Instagram: www.instagram.com/CBIHSTOCK
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278005
FAQ**
How does Cannabis Bioscience International Holdings Inc (CBIH) plan to navigate the potential regulatory changes in Texas concerning cannabis, particularly if it moves to Schedule III?
What strategic partnerships is CBIH exploring in Houston to strengthen its educational model and enhance its operational quality within the evolving cannabis industry?
How might the projected growth of the legal cannabis market in Texas, as highlighted by CBIH, influence job creation and economic development in the Houston area?
In what ways does CBIH intend to elevate its scientific standards and regulatory compliance in Houston to align with the best practices in the healthcare sector, especially in light of potential federal rescheduling?
**MWN-AI FAQ is based on asking OpenAI questions about Cannabis Bioscience International Holdings Inc (OTC: CBIH).
NASDAQ: CBIH
CBIH Trading
25.0% G/L:
$0.0005 Last:
1,022,058 Volume:
$0.0004 Open:
